Utilico Insights - Jacqueline Broers assesses why Vietnam could be the darling of Asia for investors. Watch the full video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksEco Animal Regulatory News (EAH)

Share Price Information for Eco Animal (EAH)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 84.50
Bid: 83.00
Ask: 86.00
Change: 0.50 (0.60%)
Spread: 3.00 (3.614%)
Open: 84.00
High: 85.50
Low: 84.00
Prev. Close: 84.00
EAH Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Joint Venture

3 Apr 2018 07:00

ECO Animal Health Group plc

(AIM: EAH)

ECO Animal Health establishes a joint venture for the registration and commercialization of swine vaccine products in a number of geographies.

ECO Animal Health Ltd (ECO), a wholly owned subsidiary of ECO Animal Health Group plc, and Pharmgate LLC (Pharmgate) of Wilmington, North Carolina, USA are pleased to announce the formation of a new joint venture, ECO-Pharm Limited, based in the Republic of Ireland.

ECO-Pharm Limited will be responsible for the registration, marketing, sale and distribution of a number of Pharmgate LLC swine vaccine products in the United Kingdom, the European Union and the Commonwealth of Independent States, with the addition of further geographies currently under review. It is also expected that further vaccine products will flow from our biologicals research and development pipeline.

ECO and Pharmgate jointly established Pharmgate Animal Health in the United States of America (2010) and Canada (2011). These successful operations market their owners’ range of extensively used medicated feed additives and innovative new therapeutic compounds for livestock and poultry. Pharmgate has recently licensed and commercialised their swine vaccine products in North America through these joint ventures.

Peter Lawrence, Chairman of ECO Animal Health Group plc said, “Pharmgate shares ECO’s marketing philosophy and pursuit of lean and agile field operations and is an excellent partner in North America. We are delighted to be embarking on this new venture. Vaccines are of growing importance in Europe and now represent 30% of the total market value of the European animal health sector. This range of biologicals will complement ECO’s current product portfolio of outstanding antimicrobial and antiparasitic products for swine, adding to our ability to satisfy pork producers’ needs.”

Colin Gray, President and CEO of Pharmgate commented, “This is another important moment in the evolution of Pharmgate and our relationship with ECO. We share a progressive approach to the global market in providing products and services that meet the everyday needs of the farmer and veterinarian. Our quality and streamlined supply chain, cost conscious operational approach and extensive technical services and research are at the foundation of our values”.

The information contained within this announcement is deemed by the Group to constitute inside information as stipulated under the Market Abuse Regulations (EU) No. 596/2014 ("MAR"). Upon the publication of this announcement via a Regulatory Information Service ("RIS"), this inside information is now considered to be in the public domain.

Contacts:

ECO Animal Health Group plc

Peter Lawrence   020 8336 6190
Marc Loomes 020 8447 6906
Spiro Financial
Anthony Spiro 020 8336 6196
N+1 Singer (Nominated Adviser) 020 7496 3000
Mark Taylor, Brough Ransom
Peel Hunt LLP (Joint Broker)
James Steel, Dr Christopher Golden 020 7418 8900

-----------------------------------------------------

About ECO Animal Health Ltd

ECO Animal Health based in London U.K. is a leader in the development, registration and marketing of pharmaceutical products for global animal health markets. Its products for these growth markets promote well-being in animals and include the novel antimicrobial, Aivlosin®, as well as a range of generic therapeutic products.

About Pharmgate LLC

Pharmgate LLC is the majority-owned US subsidiary of Jinhe Biotechnology Co., Ltd., P. R. China, the world leader in the production of chlortetracycline and other fermentation compounds, and more recently, the majority owner of Hangzhou UBEN Animal Vaccine Co., Ltd., a company manufacturing and supplying vaccines to the domestic market in China.

View source version on businesswire.com: https://www.businesswire.com/news/home/20180402005251/en/

Copyright Business Wire 2018

Date   Source Headline
22nd Mar 20247:00 amRNSShare Awards to Executive Directors
21st Mar 20249:13 amRNSReplacement: Trading Update
21st Mar 20247:00 amRNSTrading Update
19th Mar 20249:40 amRNSGeneral Meeting Result
27th Feb 20247:00 amRNSPublication of Notice of General Meeting
6th Feb 20247:00 amRNSTrademark Approval for ECOVAXXIN® family in the EU
8th Jan 20247:00 amRNSDisposal of Freehold Properties
5th Jan 20245:05 pmRNSHolding(s) in Company
5th Jan 20245:00 pmRNSHolding(s) in Company
22nd Dec 20237:00 amRNSDeferred Option Awards to Executive Directors
1st Dec 20237:00 amRNSDirector/PDMR Shareholding
27th Nov 202310:00 amRNSInvestor Presentation
27th Nov 20237:00 amRNSResults for the six months ended 30 September 2023
14th Nov 20233:00 pmRNSHolding(s) in Company
9th Nov 20237:00 amRNSCapital Markets Day Events
24th Oct 20237:00 amRNSNew USA and Canada label claim for Aivlosin®
28th Sep 20237:00 amRNSESG Rating
7th Sep 20232:57 pmRNSResult of AGM
10th Aug 20237:00 amRNSNotice of AGM
21st Jul 20234:25 pmRNSPosting of the Annual Report and Accounts
10th Jul 20237:00 amRNSFinal Results for the Year Ended 31 March 2023
5th Jul 20237:00 amRNSNotice of Results & Investor Presentation
6th Jun 20237:00 amRNSIssue of Equity and Total Voting Rights
18th May 20237:00 amRNSHolding(s) in Company
23rd Mar 20237:00 amRNSTrading Update
8th Mar 20237:00 amRNSAnimal Health Innovation Summit
27th Feb 202310:37 amRNSDirector/PDMR Shareholding
24th Feb 20233:19 pmRNSChange of Registered Address
17th Feb 20231:41 pmRNSHolding(s) in Company
13th Feb 20231:55 pmRNSHolding(s) in Company
9th Feb 20237:00 amRNSHolding(s) in Company
9th Feb 20237:00 amRNSHolding(s) in Company
8th Feb 20237:00 amRNSDirector/PDMR Shareholding
20th Jan 202312:14 pmRNSHolding(s) in Company
13th Dec 20223:50 pmRNSDeferred Share Option Awards
30th Nov 20223:01 pmRNSDirector/PDMR Shareholding
25th Nov 20221:37 pmRNSDirector/PDMR Shareholding
23rd Nov 20227:00 amRNSResults for the six months ended 30 September 2022
22nd Nov 20227:00 amRNSInvestor Presentation covering Interim Results
14th Nov 20227:00 amRNSChange of Auditor
31st Oct 20227:00 amRNSBlock listing Interim Review
24th Oct 20221:30 pmRNSHolding(s) in Company
24th Oct 20221:28 pmRNSHolding(s) in Company
26th Sep 20224:01 pmRNSResult of AGM
5th Sep 20221:00 pmRNSInvestor Presentation covering Full Year Results
2nd Sep 20227:00 amRNSPublication of Annual Report and Notice of AGM
31st Aug 20227:00 amRNSFinal Results for the Year Ended 31 March 2022
26th Aug 20221:13 pmRNSHolding(s) in Company
25th Aug 20227:00 amRNSHolding(s) in Company
22nd Aug 20227:00 amRNSRevised Notice of Results

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.